Curis Reports Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients with Advanced/Relapsed Solid Tumors
December 18, 2014 at 07:26 AM EST
Curis, Inc. (Nasdaq: CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human ...